Comparative Pharmacology
Head-to-head clinical analysis: BARICITINIB versus LITFULO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARICITINIB versus LITFULO.
BARICITINIB vs LITFULO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Baricitinib is a Janus kinase (JAK) inhibitor, selectively inhibiting JAK1 and JAK2, thereby modulating the signaling pathway involved in inflammatory responses.
Litfulo (ritlecitinib) is a Janus kinase (JAK) inhibitor that selectively inhibits JAK3 and to a lesser extent TEC family kinases, thereby modulating the signaling pathways involved in the immune response.
2 mg orally once daily; may increase to 4 mg once daily if inadequate response.
50 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 12.5 hours in healthy subjects; allowing once-daily dosing with steady-state reached in 2-3 days.
Clinical Note
moderateBaricitinib + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Baricitinib."
Clinical Note
moderateBaricitinib + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Baricitinib."
Clinical Note
moderateBaricitinib + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Baricitinib."
Clinical Note
moderateBaricitinib + Cyclosporine
Terminal elimination half-life is approximately 50 hours (range 40–60 h), supporting once-daily or twice-daily dosing with steady-state achieved within 10–14 days.
Approximately 75% of the dose is excreted in urine (69% as unchanged drug, 6% as metabolites), and 20% in feces (15% unchanged, 5% metabolites).
Primarily excreted unchanged in feces (≈66%) via biliary secretion, with renal excretion accounting for ≈23% as unchanged drug and metabolites; <1% excreted in urine as unchanged parent compound.
Category C
Category C
JAK Inhibitor
JAK Inhibitor
"The metabolism of Cyclosporine can be decreased when combined with Baricitinib."